Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis (original) (raw)

A COMPARATIVE STUDY ON THE EFFECTIVENESS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACEIs) AND ANGIOTENSIN RECEPTOR BLOCKERS (ARBs) IN DIABETIC NEPHROPATHY IN TYPE 2 DIABETES MELLITUS PATIENTS Original Article

International Journal of Pharmacy and Pharmaceutical Sciences (IJPPS)

International Journal of Pharmacy and Pharmaceutical Sciences, 2016

View PDFchevron_right

Comparison of Effects of ACEIs and ARBs on Albuminuria and Hyperkalemia in Indonesian Hypertensive Type 2 Diabetes Mellitus Patients

Pukovisa Prawiroharjo

International Journal of Hypertension

View PDFchevron_right

Progression of renal disease--can we forget about inhibition of the renin-angiotensin system? Authors' reply

Johannes Mann

Nephrology Dialysis Transplantation, 2006

View PDFchevron_right

Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure

David Packham

Nephrology Dialysis Transplantation, 2004

View PDFchevron_right

Reno-protective effects of renin–angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis

Johannes Mann

Diabetologia, 2011

View PDFchevron_right

Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy

Kasper Rossing

Kidney International, 2003

View PDFchevron_right

Effects of Renin-Angiotensin System Blockers on Renal Outcomes and All-cause Mortality in Patients With Diabetic Nephropathy: An Updated Meta-analysis

Panagiotis Stafylas

American Journal of Hypertension, 2008

View PDFchevron_right

Effect of Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor on Kidney Function and Blood Potassium Level in Indonesian Type 2 Diabetes Mellitus with Hypertension: A Three-Month Cohort Study

em yunir

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

View PDFchevron_right

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

Francesco Schena

The Lancet, 1999

View PDFchevron_right

Therapeutic approaches to slowing the progression of diabetic nephropathy – is less best?

Chelsea Mannebach, Eva Vivian

Drugs in Context, 2013

View PDFchevron_right

Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy

David Leehey

New England Journal of Medicine, 2013

View PDFchevron_right

Combination Therapy of Angiotensin Converting Enzyme Inhibitor and Angiotensin AT1 Receptor Antagonist in Diabetic Nephropathy

Todd MacLaughlan

Hong Kong Journal of Nephrology, 2007

View PDFchevron_right

Is there added value to adding ARB to ACE inhibitors in the management of CKD?

Debbie Cohen

Journal of the American Society of …, 2009

View PDFchevron_right

ACE Inhibitors and ARBs: Are They Better Than Other Agents to Slow Nephropathy Progression?

George Bakris

The Journal of Clinical Hypertension, 2007

View PDFchevron_right

Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro-and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials

Giorgio Gentile

View PDFchevron_right

A COMPARATIVE STUDY ON THE EFFECTIVENESS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACEIs) AND ANGIOTENSIN RECEPTOR BLOCKERS (ARBs) IN DIABETIC NEPHROPATHY IN TYPE 2 DIABETES MELLITUS PATIENTS

Pharmacist anantha

International Journal of Pharmacy and Pharmaceutical Sciences, 2016

View PDFchevron_right

Comparative Study of the Effect of Ace Inhibitors and other Antihypertensive Agents on Proteinuria in Diabetic Patients

Maximilian de Courten

The Kidney and Hypertension in Diabetes Mellitus, 1996

View PDFchevron_right

Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points

Kasper Rossing

Seminars in Nephrology, 2004

View PDFchevron_right

ACE inhibitors and ARBs: Managing potassium and renal function

deris muhammad ilyas

Cleveland Clinic Journal of Medicine, 2019

View PDFchevron_right

Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy

George Bakris

Kidney International, 1998

View PDFchevron_right

INHIBITORS AND BLOCKERS OF RENIN-ANGIOTENSIN SYSTEM IN THE PREVENTION AND IN DELAYING THE PROGRESSION OF DIABETIC NEPHROPATHY – A COMPARATIVESTUDY

Wasim Raja

International Journal of Pharmacy Practice & Drug Research

View PDFchevron_right

The Combined Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on the Progressing of Kidney Disease in Patients with Type 2 Diabetes Compared to Single Administration of Each of These Two Drugs

Samaneh Khodadadi

View PDFchevron_right

Diabetic Nephropathy – is Less Best?

eva vivian

2016

View PDFchevron_right

ACE inhibitors in non-diabetic renal disease

Richard Fluck

Heart, 1994

View PDFchevron_right

Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection

Ariela Benigni

American Journal of Physiology-Renal Physiology, 2010

View PDFchevron_right

Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: A meta-analysis

Lavanya Srinivasan

American Heart Journal, 2008

View PDFchevron_right

Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study

Asma Khan

Vascular Health and Risk Management, 2008

View PDFchevron_right